FDA approves new fixed dosing regimen for durvalumab in non-small cell lung cancer and bladder cancer

It has been approved for a 1,500mg fixed dose every four weeks for these indications. This fixed-dosing option is also being considered under regulatory review in the EU under an accelerated assessment. Durvalumab is not currently licensed for use in bladder cancer in the EU.

Source:

PharmaTimes